Thomas Frisell

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 31

Top Venues

Annals of the rheumatic diseases

European journal of neurology

Annals of neurology

RMD open

Karolinska Institutet (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Karolinska Institutet Jan 01 2008 - Jun 08 2012

Sweden

PHD :: Medical Epidemiology and Biostatistics

Uppsala Universitet Aug 20 2002 - Jun 01 2007

Sweden

MSC

Publications

Peter Alping, Martin Neovius, Fredrik Piehl, Thomas Frisell
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study. Annals of neurology (2024)
Peter Alping, Martin Neovius, Fredrik Piehl, Thomas Frisell
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study. Annals of neurology 95 (6) (2024)
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, Malin Boremalm, Pierre de Flon, Yunzhang Wang, Jonatan Salzer, Jan N Lycke, Katharina Fink, Thomas Frisell, Faiez Al Nimer, Anders Svenningsson
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. European journal of neurology 31 (8) (2024)
Fredrik Piehl, Peter Alping, Suvi Virtanen, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette M Langer-Gould, Jan Lycke, Johan Mellergård, Petra Nilsson, Tomas Olsson, Jonatan Salzer, Anders Svenningsson, Thomas Frisell
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab. Annals of neurology (2024)
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, Malin Boremalm, Pierre de Flon, Yunzhang Wang, Jonatan Salzer, Jan N Lycke, Katharina Fink, Thomas Frisell, Faiez Al Nimer, Anders Svenningsson
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. European journal of neurology 31 (8) (2024)
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, Malin Boremalm, Pierre de Flon, Yunzhang Wang, Jonatan Salzer, Jan N Lycke, Katharina Fink, Thomas Frisell, Faiez Al Nimer, Anders Svenningsson
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. European journal of neurology 31 (8) (2024)
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, Malin Boremalm, Pierre de Flon, Yunzhang Wang, Jonatan Salzer, Jan N Lycke, Katharina Fink, Thomas Frisell, Faiez Al Nimer, Anders Svenningsson
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. European journal of neurology (2024)
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, Malin Boremalm, Pierre de Flon, Yunzhang Wang, Jonatan Salzer, Jan N Lycke, Katharina Fink, Thomas Frisell, Faiez Al Nimer, Anders Svenningsson
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study. European journal of neurology 31 (8) (2024)
Yihan Hu, Thomas Frisell, Peter Alping, Huan Song, Yudi Pawitan, Fang Fang, Fredrik Piehl
Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis. Annals of neurology (2024)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Johan Askling
Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis. RMD open 9 (4) (2023)
Viking Huss, Hannah Bower, Karin Hellgren, Thomas Frisell, Johan Askling, null null, null null
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study. Annals of the rheumatic diseases (2023)
Thomas Frisell, Hannah Bower, Matilda Morin, Eva Baecklund, Daniela Di Giuseppe, Bénédicte Delcoigne, Nils Feltelius, Helena Forsblad-d'Elia, Elisabet Lindqvist, Ulf Lindström, Johan Askling, null null
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Annals of the rheumatic diseases (2023)
Andrei Barbulescu, Arvid Sjölander, Bénédicte Delcoigne, Johan Askling, Thomas Frisell
Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis-a marginal structural model application. Rheumatology (Oxford, England) (2023)
Teresa A Simon, Lixian Dong, Samy Suissa, Kaleb Michaud, Sofia Pedro, Marc Hochberg, Maarten Boers, Johan Askling, Thomas Frisell, Anja Strangfeld, Yvette Meißner, Vadim Khaychuk, Alyssa Dominique, Michael A Maldonado
Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies. Annals of the rheumatic diseases (2023)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD open 9 (4) (2023)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD open 9 (4) (2023)
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Bénédicte Delcoigne, Ulf Lindström, Carl Turesson, Katerina Chatzidionysiou, Elisabet Lindqvist, Ann Knight, Helena Forsblad-d'Elia, Johan Askling
Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden. RMD open 9 (4) (2023)
Denis Mongin, Kim Lauper, Axel Finckh, Thomas Frisell, Delphine Sophie Courvoisier
Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study. Annals of the rheumatic diseases 81 (5) (2022)
Delphine Sophie Courvoisier, Kim Lauper, Joanna Kedra, Maarten P T de Wit, Bruno Fautrel, Thomas Frisell, Kimmie L Hyrich, Florenzo Iannone, Pedro M Machado, Lykke Midtbøll Ørnbjerg, Žiga Rotar, Maria Jose Santos, Tanja Alexandra Stamm, Simon R Stones, Anja Strangfeld, Sytske Anne Bergstra, Robert B M Landewe, Axel Finckh
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Annals of the rheumatic diseases 81 (6) (2022)
Elisa Longinetti, Hannah Bower, Kyla A McKay, Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette M Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Johan Mellergård, Tomas Olsson, Fredrik Piehl, Thomas Frisell
COVID-19 clinical outcomes and DMT of MS patients and population-based controls. Annals of clinical and translational neurology 9 (9) (2022)
Viktor Molander, Hannah Bower, Thomas Frisell, Bénédicte Delcoigne, Daniela Di Giuseppe, Johan Askling, null null
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Annals of the rheumatic diseases (2022)
Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Johan Askling
Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19? Annals of the rheumatic diseases (2021)
Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Gerd-Marie Ahlenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad-d'Elia, Alf Kastbom, Lars Klareskog, Elisabet Lindqvist, Ulf Lindström, Carl Turesson, Christopher Sjöwall, Johan Askling, null null
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Annals of the rheumatic diseases (2021)
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Thomas Frisell
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of neurology 87 (5) (2020)
Viktor Molander, Hannah Bower, Thomas Frisell, Johan Askling
Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Annals of the rheumatic diseases 80 (2) (2020)
Helga Westerlind, Marie Holmqvist, Lotta Ljung, Thomas Frisell, Johan Askling
Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome. Annals of the rheumatic diseases 78 (5) (2019)
Helga Westerlind, Marie Holmqvist, Lotta Ljung, Thomas Frisell, Johan Askling
Response to: 'Inflammatory and non-inflammatory triggers of acute coronary syndromes' by Eyuboglu. Annals of the rheumatic diseases 79 (5) (2019)
Thomas Frisell, Eva Baecklund, Karin Bengtsson, Daniela Di Giuseppe, Helena Forsblad-d'Elia, Johan Askling, null null
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Annals of the rheumatic diseases 77 (5) (2017)
Aase Haj Hensvold, Thomas Frisell, Patrik K E Magnusson, Rikard Holmdahl, Johan Askling, Anca Irinel Catrina
How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins. Annals of the rheumatic diseases 76 (1) (2016)
Hjalmar Wadström, Thomas Frisell, Pär Sparén, Johan Askling, null null
Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Annals of the rheumatic diseases 75 (7) (2016)
Kaleb D Michaud, Niklas Berglind, Stefan Franzén, Thomas Frisell, Christopher Garwood, Jeffrey D Greenberg, Meilien Ho, Marie Holmqvist, Laura Horne, Eisuke Inoue, Fredrik Nyberg, Dimitrios A Pappas, George Reed, Deborah P M Symmons, Eiichi Tanaka, Trung N Tran, Suzanne M M Verstappen, Eveline Wesby-van Swaay, Hisashi Yamanaka, Johan Askling
Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Annals of the rheumatic diseases 75 (10) (2016)
Johan Askling, Niklas Berglind, Stefan Franzen, Thomas Frisell, Christopher Garwood, Jeffrey D Greenberg, Meilien Ho, Marie Holmqvist, Laura Horne, Eisuke Inoue, Kaleb D Michaud, Fredrik Nyberg, Dimitrios A Pappas, George Reed, Eiichi Tanaka, Trung N Tran, Suzanne M M Verstappen, Hisashi Yamanaka, Eveline Wesby-van Swaay, Deborah P M Symmons
How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Annals of the rheumatic diseases 75 (10) (2015)
Thomas Frisell, Saedis Saevarsdottir, Johan Askling
Does a family history of RA influence the clinical presentation and treatment response in RA? Annals of the rheumatic diseases 75 (6) (2015)
Thomas Frisell, Karin Hellgren, Lars Alfredsson, Soumya Raychaudhuri, Lars Klareskog, Johan Askling
Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden. Annals of the rheumatic diseases 75 (1) (2014)

Thomas Frisell.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas Frisell